Pfizer Inc. closed 28.57% short of its 52-week high of $31.54, which the company reached on July 30th.

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at ...

Chemicals firms Dow and LyondellBasell are the biggest dividend payers in the S&P 500. Other fat divided payouts include ...

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

When leveraged to their appropriate context and strengths, under the care of an oncologist, cancer-related apps can actually strengthen the bond with the physician and care team, while empowering the ...

Explore how Trump's tariffs affect corporate strategies and consumer prices in America amid changing import dynamics.

Faced with new tariffs imposed by President Donald Trump, Corporate America is adjusting strategies. This includes potential ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Pfizer (PFE) with a Neutral rating and $24 price target Pfizer made “concrete ...

Pfizer's stock has suffered a brutal 16.44% drop in April, despite flexing strong Q4 earnings with a 37.2% EPS beat. Over the ...